Expert Consulting and Modeling Services for Small Molecule Drug Discovery

Computational sciences strategy

With over 30 years of experience, MolCognitiX possessed a depth knowledge of a broad computational techniques for small molecule drug discovery. We specializes in assessing and evaluating computational technologies with a focus on their potential impacts in practices. We emphasize human cognitive intelligence, fundamental science augmented by machine learning techniques for a successful application in drug discovery. We will help an organization to develop strategies through internal and/or external investments to drive the medicinal chemistry and molecular design to a new level.

Strategic computational modeling for molecular design

Leverage the practical knowledge and proven impacts of computational techniques in molecular design, MolCognitiX provides consultation on advanced and pragmatic techniques for small drug discovery to optimize design strategy, reduce Design-Make-Test cycle time, and maximize return of investment.

Deep knowledges in molecular properties, molecular interaction to accelerate your project delivery

With a track record of contributing to design of clinical candidates for broad range targets in various disease areas, and deep knowledge of technical expertise in major computational chemistry areas, we provide computational modeling service to support your drug discovery effort.

About MolCognitiX

MolCognitiX is founded by Dr. Xinjun Hou, an experienced scientist with 30+ years of experience in computational and AI-driven small molecule drug discovery.

As a senior scientific director at Pfizer, Dr. Xinjun Hou built a strong portfolio of computational innovations through Pfizer’s Computational Chemistry Network Group and external partnerships. He spearheaded AI partnerships with PostEra, MIT, and University of Cambridge. He developed strategic initiative to strength core computational chemistry capability with XtalPi, Stanford University, and other partners to advance sciences in crystal structure prediction (CSP), molecular dynamics, molecular mechanics force field, and potency prediction.

Dr. Xinjun Hou is a devoted computational scientist committed to demonstrate impacts in molecular design through computational modeling. He and his team of computational chemists applied SBDD, LBDD, Virtual Screening, QSAR, Generative Chemistry and AI/ML models to deliver more than 20 small molecule clinical candidates of multiple target families in neuroscience, cardiovascular and metabolic, and antiviral disease areas.

Dr. Xinjun Hou was a cofounder of SABPA, SoCal Association for Biomedical and Pharmaceutical Advancements, a 501(c)(3) nonprofit organization launched in 2002 and now has over 4,000 members and subscribers, including scholars, professionals, and entrepreneurs within Southern California's biotech and pharmaceutical industries.